Literature DB >> 8567332

The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma.

M Koukourakis1, G Hlouverakis, L Kosma, J Skarlatos, J Damilakis, A Giatromanolaki, D Yannakakis.   

Abstract

PURPOSE: We evaluated the impact of overall treatment time on the disease-free survival (DFS) and local control after radiotherapy for nonsmall cell lung carcinoma. METHODS AND MATERIALS: One hundred fifty-three cases considered as responders to radiotherapy were retrospectively analyzed. Patients with Karnofsky status < 70, pretreated with chemotherapy and with pleural or pericardial effusion, were excluded from the analysis. Radiation dose homogenization was done with calculation of the normalized total dose without (NTD) and with time correction (NTD-T) for alpha/beta = 10 Gy.
RESULTS: Kaplan-Meier curves for 2-year DFS showed that any analysis based on radiation dose can prove to be erroneous when the time factor is neglected. Although there was no difference between the 47-55 Gy and 56-64 Gy NTD groups, a log rank test revealed a strong difference (p < 0.0002) between NTD-T groups. No difference was observed for patients with mediastinal involvement. Logistic regression analysis showed a statistical association of dose on 2-year local progression-free probability for different time compartments. For those cases without mediastinal involvement, the daily dose lost because of treatment protraction beyond 20 days after the beginning of radiotherapy was estimated to 0.2 Gy/day. When all cases were considered together this was calculated to 0.45 Gy/day.
CONCLUSION: Time factor should not be underestimated when evaluating the results of radiotherapy for nonsmall cell lung cancer. There is strong evidence that prolonged overall treatment time could be a major cause of the failure of radiotherapy to control the local disease.

Entities:  

Mesh:

Year:  1996        PMID: 8567332     DOI: 10.1016/0360-3016(95)02102-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

Review 1.  Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer.

Authors:  Rosemary Stevens; Fergus Macbeth; Elizabeth Toy; Bernadette Coles; Jason F Lester
Journal:  Cochrane Database Syst Rev       Date:  2015-01-14

2.  Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer.

Authors:  Matthew P Deek; Sinae Kim; Inaya Ahmed; Bruno S Fang; Wei Zou; Jyoti Malhotra; Joseph Aisner; Salma K Jabbour
Journal:  Am J Clin Oncol       Date:  2018-04       Impact factor: 2.339

3.  A Randomized Phase 2 Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy-Induced Esophagitis During the Treatment of Lung Cancer: Results of NRG Oncology RTOG 1012.

Authors:  Shannon E Fogh; Snehal Deshmukh; Lawrence B Berk; Amylou C Dueck; Kevin Roof; Sherif Yacoub; Thomas Gergel; Kevin Stephans; Andreas Rimner; Albert DeNittis; John Pablo; Justin Rineer; Terence M Williams; Deborah Bruner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-23       Impact factor: 7.038

4.  Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer.

Authors:  Yanqun Dong; Nicholas G Zaorsky; Tianyu Li; Thomas M Churilla; Rosalia Viterbo; Mark L Sobczak; Marc C Smaldone; David Yt Chen; Robert G Uzzo; Mark A Hallman; Eric M Horwitz
Journal:  J Med Imaging Radiat Oncol       Date:  2017-10-13       Impact factor: 1.735

5.  Short term clinical outcomes of accelerated hypofractionated radiotherapy in inoperable non-small cell lung cancer patients.

Authors:  Shoon Mya Aye; Lin Lin Kyi; Moe Hlaing; Aye Aye Myint; Khin Cho Win
Journal:  Rep Pract Oncol Radiother       Date:  2021-09-30

6.  Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.

Authors:  Jeffrey A Bogart; Dorothy Watson; Edward F McClay; Lisa Evans; James E Herndon; Frances Laurie; Stephen L Seagren; T J Fitzgerald; Everett Vokes; Mark R Green
Journal:  Lung Cancer       Date:  2008-03-25       Impact factor: 5.705

7.  Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.

Authors:  Matthew P Deek; Brian Benenati; Sinae Kim; Ting Chen; Inaya Ahmed; Wei Zou; Joseph Aisner; Salma K Jabbour
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-09-25       Impact factor: 7.038

8.  The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer.

Authors:  Bing Xia; Gui-Yuan Chen; Xu-Wei Cai; Jian-Dong Zhao; Huan-Jun Yang; Min Fan; Kuai-Le Zhao; Xiao-Long Fu
Journal:  Radiat Oncol       Date:  2011-05-19       Impact factor: 3.481

9.  Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.

Authors:  Erkan Topkan; Cem Parlak; Savas Topuk; Berrin Pehlivan
Journal:  BMC Cancer       Date:  2012-10-31       Impact factor: 4.430

10.  Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.

Authors:  M I Saunders; A Rojas; B E Lyn; K Pigott; M Powell; K Goodchild; P J Hoskin; H Phillips; N Verma
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.